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Abstract: Pregnant women and their infants are at increased risk for severe influenza-related com-
plications. A decade has passed since influenza vaccination was first recommended for pregnant
women in Germany in 2010; however, monitoring of vaccination coverage (VC) has not yet been
implemented for this target group. Using nationwide outpatient claims data, we here provide results
on influenza VC among pregnant women in Germany for seasons 2014/15 to 2019/20. For any
given season, pregnant women were defined as women who had undergone prenatal health care
in at least two consecutive quarters within a season. VC increased from 9.0% in season 2014/15
to 16.6% in 2019/20 (+84%), while most of the increase occurred from season 2016/17 (VC: 9.9%)
onwards (+68%). Consistently across seasons, women in east Germany were 40 to 60% more likely
to be vaccinated compared to women residing in west Germany. According to age, the highest VC
was observed among women aged 35 to <40 years (2019/20: 18.2%). Despite noticeable increases in
influenza VC during recent years, overall coverage remains low among pregnant women. Starting
with this analysis, VC among pregnant women in Germany will be monitored on a yearly basis in
order to detect trends and identify immunization gaps.
Keywords: claims data; Germany; influenza; pregnancy; vaccination coverage
1. Introduction
Pregnant women and their infants are at increased risk for severe influenza-related
complications and hospitalization [1]. The vaccination of pregnant women against seasonal
influenza has therefore become a key strategy to prevent influenza and influenza-related
complications in pregnant women and their infants in many high-income countries [2–4].
Compelling evidence indicates that influenza vaccination during pregnancy is safe and
effective in preventing influenza illness and related complications in both pregnant women
and their newborns [5–7]. Despite this, vaccination coverage (VC) has generally been
observed to be suboptimal [2,8–10]. In the European Union (EU) and European Economic
Area (EEA), for instance, the median VC was 25% in season 2016/17, ranging from 0.5% in
Slovenia to 59% in Northern Ireland [2,10]. Of note, although 28 of 30 EU/EEA Member
States recommend routine immunization of pregnant women against seasonal influenza,
a monitoring system of VC has rarely been implemented and estimates for the EU/EEA
region are solely based on nine Member States [2,10].
In Germany, the National Immunization Technical Advisory Group (Standing Com-
mittee on Vaccination, STIKO) recommends vaccination against seasonal influenza for
individuals aged ≥60 years, individuals with underlying chronic diseases, residents of
nursing homes, healthcare workers, and, since 2010, pregnant women [11]. Specifically, all
pregnant women should be vaccinated against seasonal influenza from the second trimester,
and in case of an underlying chronic condition, from the first trimester onwards [12]. The
annual influenza vaccination is free of charge for all population subgroups included in
the STIKO recommendation and fully covered by statutory health insurance (SHI), which
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comprises about 87% of the population in Germany. In 2004, a nationwide immunization
information system for the monitoring of VC based on outpatient claims data comprising
all SHI-insured individuals was launched [13]. From 2019 onwards, VC of all vaccinations
as recommended by the STIKO has been published on an annual basis [14,15]. Although a
decade has passed since influenza vaccination was first recommended for pregnant women
in Germany, a regular monitoring of VC in this target group has not been implemented yet.
So far, data on national influenza VC during pregnancy is limited to a few studies covering
single [16–18] or a few consecutive seasons [19].
In an effort to address the lack of VC monitoring among pregnant women in Germany,
the present study is the prelude to annual reporting of VC in this target group. Using
nationwide outpatient claims data, we here provide recent data on influenza VC among
pregnant women for seasons 2014/15 to 2019/20. By this, we aim (a) to evaluate how well
recommendations have been implemented in practice and (b) to monitor trends in VC over
time. The knowledge derived from these data may further guide the development and
refinement of tailored strategies to increase vaccination uptake and, ultimately, to reduce
the burden from influenza-related complications during pregnancy.
2. Materials and Methods
2.1. Data Basis
For the present analysis, we used nationwide outpatient claims data of all statutory
health insured (SHI) individuals, covering 87% of the German population. The data
include date-specific information on outpatient vaccinations and diagnoses by quarter,
outpatient services according to the Doctors’ Fee Scale within the SHI scheme, as well
as information on the patient’s year and month of birth, sex, and region of residence
(17 regions representing the different Associations of Statutory Health Insurance Physicians,
ASHIPs, in Germany). With the exception of North-Rhine Westphalia, which consists of two
ASHIP regions, the administrative ASHIP regions correspond to the 16 federal states. As the
availability of necessary data differed between ASHIPs, we included data from 16 ASHIPs
in the analyses of seasons 2017/18 to 2019/20, while data from 13, 14, and 15 ASHIPs were
included in the analyses of seasons 2014/15, 2015/16 and 2016/17, respectively. Hence,
our analysis was based on data covering 66% (2014/15) to 80% (from 2017/18 onwards) of
the total population in Germany, respectively.
2.2. Definition of Pregnancy during Influenza Season
In Germany, prenatal care including pregnancy-related vaccination is guided by
maternity care guidelines that define a nationwide standardized program for all pregnant
women. This program is fully funded by health insurance and primarily conducted by
office-based gynecologists [20]. Pregnancy-related health care services covered by the
program are coded according to the Doctors’ Fee Scale using the position “01770”. This
code can be used for the purpose of billing services of prenatal care once per calendar
quarter of pregnancy.
Hence, we defined pregnancy on a quarterly basis based on outpatient services for
prenatal care coded as “01770” among women of childbearing age (15 to 49 years). For any
given influenza season (third quarter until first quarter of the following year), women who
were pregnant during the season and thus eligible for influenza vaccination were defined
as women who had undergone prenatal examinations in at least two consecutive quarters
of that season.
2.3. Calculation of Vaccination Coverage
For each season, VC was defined as the number of women who were pregnant during
the respective season and received influenza vaccination during that season over the total
number of women who were pregnant during that season. VC was calculated for Germany
as a whole, as well as according to region (east vs. west) and age group (15 to <20, 20 to
<25, 25 to <30, 30 to <35, 35 to <40, and 40+ years). For the comparison of east and west
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Germany, ASHIPs were classified into eastern (Berlin, Brandenburg, Mecklenburg-Western
Pomerania, Saxony, Saxony-Anhalt and Thuringia) and western federal states (Baden-
Wuerttemberg, Bavaria, Bremen, Hamburg, Hesse, North Rhine-Westphalia, Rhineland-
Palatinate, Saarland, Schleswig-Holstein).
In sensitivity analyses, we evaluated the effect of vaccination before pregnancy by
additionally including women who had their pregnancy first documented in the fourth
quarter of the year and had been vaccinated during the adjacent third quarter. Additionally,
in order to rule out that the comparison in VC across seasons was biased due to differences
in included ASHIPs in analyses of the first three seasons (2014/15, 2015/16, 2016/17)
compared to the last three seasons (2017/18, 2018/19, 2019/20), we reran the analysis
solely including those 13 ASHIPs with available data in all six seasons.
3. Results
Table 1 shows the number of pregnant women identified as eligible for influenza
vaccination during the influenza seasons under study and their distribution according to
region and age. The considerably lower number of pregnant women in the early compared
to the later seasons can be attributed to the fact that not all ASHIPs had provided the
necessary data for inclusion into study for the earlier seasons. Consistently across seasons,
the highest proportion of pregnancies was accounted for by age group 30 to <35 years
(35 to 37%), followed by age groups 25 to <30 years (27 to 30%) and 35 to <40 years (18 to
20%). In addition, the proportion of pregnancies among women aged 30 years and above
increased over the observation period (56.2% vs. 61.8% in 2019/20).
Table 1. Number and distribution of pregnant women eligible for influenza vaccination based on outpatient claims data, by
region and age group, seasons 2014/15 to 2019/20.
2014/15 2015/16 2016/17 2017/18 2018/19 2019/20
N % N % N % N % N % N %
Total 481,197 100 509,897 100 600,660 100 626,135 100 615,331 100 614,239 100
By region
Eastern federal states 124,286 25.8 128,706 25.2 131,938 22.0 129,251 20.6 124,873 20.3 121,216 19.7
Western federal states 356,911 74.2 381,191 74.8 468,722 78.0 496,884 79.4 490,458 79.7 493,023 80.3
By age group
15 to <20 10,102 2.1 10,523 2.1 12,763 2.1 12,027 1.9 10,884 1.8 10,129 1.6
20 to <25 54,259 11.3 53,620 10.5 64,227 10.7 64,688 10.3 61,317 10.0 59,062 9.6
25 to <30 146,087 30.4 154,925 30.4 180,289 30.0 181,336 29.0 171,544 27.9 165,973 27.0
30 to <35 168,996 35.1 178,837 35.1 209,734 34.9 222,692 35.6 224,379 36.5 229,442 37.4
35 to <40 84,832 17.6 93,921 18.4 112,272 18.7 121,233 19.4 122,219 19.9 123,367 20.1
40+ 16,921 3.5 18,071 3.5 21,375 3.6 24,159 3.9 24,988 4.1 26,266 4.3
Overall, 16.6% of women who were pregnant during influenza season 2019/20 were
vaccinated during that season (Table 2). Compared to season 2014/15, VC increased by
84%, while most of the increase occurred from season 2016/17 (VC: 9.9%) onwards (+68%).
Women in eastern federal states were 40 to 60% more likely to have been vaccinated
compared to women residing in western federal states. At the level of ASHIPs, variation
in VC was 3.5-fold in season 2014/15 and continuously decreased to 2.2-fold in season
2019/20, with coverage ranging from 5.5% to 12.9% in 2014/15 and 13.3% to 29.5% in
2019/20 (data not shown). Consistently across seasons, coverage was highest among
women aged 35 to <40 years (2019/20: 18.2%). Compared to 2014/15, VC particularly
increased in age groups ≥30 years (+90% to +98%) compared to younger age groups (+64%
to +75%). Overall, the higher VC in eastern compared to western federal states found in
the total study population was similarly observed across all age groups (Figure 1). On
a relative scale, the difference between the two regions slightly decreased among all age
groups during the study period. However, women in eastern federal states were still 35%
(40+ years) to 54% (25 to <30 years) more likely to have been vaccinated in season 2019/20
compared to their western counterparts. Despite this regional difference in coverage, the
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overall pattern across age groups was comparable between both regions with the highest
coverage observed among women aged 35 to <40 years (23.2% and 17.0%, respectively).
Table 2. Influenza vaccination coverage (%) during pregnancy based on outpatient claims data, by region and age group,
seasons 2014/15 to 2019/20.
2014/15 2015/16 2016/17 2017/18 2018/19 2019/20
Total (nationwide, all age groups) 9.0 9.0 9.9 11.8 14.1 16.6
By region
Eastern federal states 12.5 12.8 13.4 16.1 20.0 22.1
Western federal states 7.7 7.8 8.9 10.7 12.6 15.3
By age group
15 to <20 9.0 9.4 10.3 12.3 12.6 14.8
20 to <25 8.8 8.5 9.5 11.4 12.4 14.7
25 to <30 8.8 8.7 9.4 11.2 12.8 15.4
30 to <35 9.0 9.2 10.0 12.1 14.6 17.1
35 to <40 9.4 9.7 10.6 12.5 15.8 18.2
40+ 8.9 8.8 9.9 12.1 15.1 17.7
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Results remained virtually unchanged when we accounted for vaccination before
pregnancy. Specifically, VC increased in all seasons by roughly 0.2 percentage points when
we included women who were vaccinated in the third quarter and for whom prenatal care
was first documented in the fourth quarter. Vaccination coverage remained unchanged
when we restricted the study population to those 13 ASHIPs with available data in all
six seasons under study. Specifically, vaccination coverage amounted to 9.0% (2015/16),
9.7% (2016/17), 11.6% (2017/18), 14.0% (2018/19) and 16.4% (2019/20).
4. Discussion
As an initial step towards the annual reporting of influenza VC among pregnant
women in Germany, the present study provides data for seasons 2014/15 to 2019/20.
Although we observed a continuous and marked increase in VC from season 2016/17 to
2019/20, coverage still remained low and, additionally, displayed considerable regional
variation. In 2019/20, nine years after the endorsement of the official recommendation in
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2010, more than 80% of pregnant women were unprotected and thus more vulnerable to
influenza infection and possible severe complications.
In a previous claims-based study, Bätzing et al. reported VC for the years 2010 to
2014 [19]. In that study, 9.4% of women who were pregnant in 2014 were vaccinated against
influenza, an observation that is perfectly in line with our findings among women who
were pregnant during season 2014/15. Findings from earlier population-based surveys in
Germany generally indicated a higher coverage, ranging from 11 to 20% during influenza
seasons 2012/13 and 2013/14 [16–18]. In brief, among 1025 women, 23% reported vaccina-
tion against influenza during the 2012/13 season, with 16% receiving the vaccination while
being pregnant [18]. Comparable results were obtained based on documented information
in vaccination certificates from a cross-sectional study comprising 253 pregnant women
from two perinatal centers, in which 19.5% had a recorded influenza vaccination during
pregnancy [16]. In a nationwide web-based prospective cohort study conducted between
2012 and 2014, 11% of 838 women reported influenza vaccination during pregnancy [17].
Considering that these surveys were of a small sample size and, inherently due to their
design, may be limited by selection and/or recall bias, we would expect a higher VC in
these primary non-representative studies compared to the present large-scale secondary
data analysis.
Strikingly, after years of relatively stable VC levels of ~9% (see also Bätzing et al., [19]
for the years 2010 to 2014), coverage increased constantly from season 2017/18 onwards.
Although it currently remains unclear whether this trend is of a sustained nature or merely
represents a pronounced fluctuation, it is tempting to speculate that intensified information
campaigns, as have been initiated and orchestrated by the Professional Association of
Gynecologists in season 2017/18, have begun to bear fruit [21]. While the average VC
was 9.3% up to season 2016/17 (2014/15 to 2016/17), it was 14.2% from season 2017/18
onwards (2017/18 to 2019/20). In brief, this campaign aimed to increase public awareness
and knowledge on influenza illness and vaccination during pregnancy, e.g., through means
of several press releases distributed over the whole influenza season, the publication
of interviews as well as the expansion and improvement of information on the central
information website of the Professional Association of Gynecologists. The increase in
media response observed during and after this campaign may have contributed to the
observed increase in VC. Secondly, VC may be partly attributed to the increase in age at
pregnancy observed during the study period. Specifically, the shift in age distribution
towards a higher proportion of pregnant women aged ≥ 30 years in conjunction with the
generally higher VC in this age group may in part explain the overall increase in VC.
When comparing VC among pregnant women between industrialized countries, low
to moderate coverage and high variations are observed. Based on data from nine EU/EEA
Member States, the median VC was 25% in season 2016/17 and varied between 0.5% in
Slovenia and 59% in Northern Ireland [2]. In the US, coverage estimated from annually
conducted Internet panel surveys ranged between 40 and 50% between 2010/11 and
2017/18, before increasing to 61% in season 2019/20 [8,9]. The substantial between-country
differences in VC may be partially attributed to different study designs to assess coverage,
differences in communication activities supporting the recommendation, in vaccination
systems, funding schemes, and different attitudes towards vaccination during pregnancy as
well as the time evolved since endorsement of the recommendation, which may affect the
acceptance of the vaccination and ultimately the coverage [18]. While in the US, influenza
vaccination was recommended for pregnant women in the second trimester of pregnancy
from 1997 and regardless of the trimester from 2014 onwards [22,23], it is recommended in
Germany for a much shorter time. Interestingly, VC was equally low in the US within the
first 10 years after endorsement of the recommendation (~15%; [24]) and thus comparable
in size to the coverage currently observed in Germany.
Several factors have been shown to be associated with VC among pregnant women,
including poor vaccine-related knowledge, vaccine safety concerns, mistrust in the vaccines,
and perceptions related to the severity of disease [18,25–29]. Evidence further consistently
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emphasizes the crucial role of physicians, i.e., gynecologists, in increasing VC among
pregnant women. Specifically, gynecologists are considered the most frequently used
source to obtain information on influenza vaccination during pregnancy and studies have
shown that women receiving a vaccination advice from a physician are more likely to be
vaccinated [16–18,26,29].
In 2003, the World Health Assembly urged the Member States to increase influenza VC
of all people at high risk, including the elderly and individuals with underlying diseases,
and to attain VC among the elderly of at least 75% by 2010 [30]. In the EU/EAA region,
countries have not managed to achieve the coverage target in any target group and the
uptake of vaccination varies greatly between countries [2]. For Germany, two recent
analyses similarly indicate that further efforts are needed to increase coverage of influenza
vaccination in these target groups. Despite VC increasing among individuals aged ≥ 60
years the second season in succession, it reached on average 39% in season 2019/20 [15].
Among individuals with a chronic condition, VC ranged from 19% in individuals with
multiple sclerosis to 44% in individuals with chronic kidney disease in season 2017/18
with a tendency towards a decline during the observation period [31].
Routinely collected health claims data offer the unique opportunity to estimate the
uptake of vaccinations under real-world conditions based on large sample sizes. The
present data is based on data from nearly all SHI-insured individuals, reflecting up to
80% of the total German population. Hence, selection bias is negligible compared to
population-based surveys and studies based on single SHI funds. However, results have to
be interpreted against the backdrop of the following limitations. First, the identification of
pregnant women was based on the presence of two consecutive quarters with pregnancy-
related health care services and, thus, based on continuous care through an SHI-authorized
physician in at least two consecutive quarters of pregnancy. Pregnant women with a low
compliance might therefore be underrepresented in the present study, which might have
resulted in an overestimation of VC. Second, the majority of pregnant women usually
continue their professional activities during the first and second trimester of pregnancy,
which is the time most relevant for influenza vaccination. In Germany, some public
employers and companies offer free on-site influenza vaccinations for their employees,
which are administered through company medical officers and, therefore, are not included
in the present data. Third, due to differences in the pseudonymization procedure between
ASHIPs, it is currently not possible to follow-up individuals who move from one ASHIP
region to another. Hence, we could not include women receiving two consecutive quarters
of outpatient services for prenatal care in more than one ASHIP (e.g., due to moving
between ASHIPs). However, it is unlikely that this could have exerted a noticeable effect
on our results.
5. Conclusions
Although a constant increase in influenza vaccination uptake among pregnant women
in Germany was noted from 2016/17 onward, vaccine uptake remains very low. Starting
with this analysis, influenza VC among pregnant women in Germany will be monitored and
reported on a yearly basis to evaluate the progress in achieving a higher coverage. Further
efforts, i.e., involving intensified information through gynecologists and an improved
understanding of barriers to vaccination through questionnaire-based studies, may guide
the development and refinement of tailored strategies to support a sustainably improved
coverage and reduce influenza and influenza-related complications during pregnancy.
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